Literature DB >> 16160149

Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail.

Stéphanie Wyss1, Antony S Dimitrov, Frédéric Baribaud, Terri G Edwards, Robert Blumenthal, James A Hoxie.   

Abstract

Truncation of the human immunodeficiency virus (HIV) or simian immunodeficiency virus (SIV) gp41 cytoplasmic tail (CT) can modulate the fusogenicity of the envelope glycoprotein (Env) on infected cells and virions. However, the CT domains involved and the underlying mechanism responsible for this "inside-out" regulation of Env function are unknown. HIV and SIV CTs are remarkably long and contain amphipathic alpha-helical domains (LLP1, LLP2, and LLP3) that likely interact with cellular membranes. Using a cell-cell fusion assay and a panel of HIV Envs with stop codons at various positions in the CT, we show that truncations of gp41 proximal to the most N-terminal alpha helix, LLP2, increase fusion efficiency and expose CD4-induced epitopes in the Env ectodomain. These effects were not seen with a truncation distal to this domain and before LLP1. Using a dye transfer assay to quantitate fusion kinetics, we found that these truncations produced a two- to fourfold increase in the rate of fusion. These results were observed for X4-, R5-, and dual-tropic Envs on CXCR4- and CCR5-expressing target cells and could not be explained by differences in Env surface expression. These findings suggest that distal to the membrane-spanning domain, an interaction of the gp41 LLP2 domain with the cell membrane restricts Env fusogenicity during Env processing. As with murine leukemia viruses, where cleavage of a membrane-interactive R peptide at the C terminus is required for Env to become fusogenic, this restriction of Env function may serve to protect virus-producing cells from the membrane-disruptive effects of the Env ectodomain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16160149      PMCID: PMC1211532          DOI: 10.1128/JVI.79.19.12231-12241.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  100 in total

1.  The membrane-proximal intracytoplasmic tyrosine residue of HIV-1 envelope glycoprotein is critical for basolateral targeting of viral budding in MDCK cells.

Authors:  R Lodge; J P Lalonde; G Lemay; E A Cohen
Journal:  EMBO J       Date:  1997-02-17       Impact factor: 11.598

2.  Calmodulin-binding function of LLP segments from the HIV type 1 transmembrane protein is conserved among natural sequence variants.

Authors:  S B Tencza; T A Mietzner; R C Montelaro
Journal:  AIDS Res Hum Retroviruses       Date:  1997-02-10       Impact factor: 2.205

3.  Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions.

Authors:  E O Freed; M A Martin
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

4.  Functional analysis of the cytoplasmic tail of Moloney murine leukemia virus envelope protein.

Authors:  M M Januszeski; P M Cannon; D Chen; Y Rozenberg; W F Anderson
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

5.  Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC.

Authors:  J F Rowell; P E Stanhope; R F Siliciano
Journal:  J Immunol       Date:  1995-07-01       Impact factor: 5.422

6.  A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells.

Authors:  C C LaBranche; M M Sauter; B S Haggarty; P J Vance; J Romano; T K Hart; P J Bugelski; M Marsh; J A Hoxie
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

7.  The human and simian immunodeficiency virus envelope glycoprotein transmembrane subunits are palmitoylated.

Authors:  C Yang; C P Spies; R W Compans
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

8.  Rescue of human immunodeficiency virus type 1 matrix protein mutants by envelope glycoproteins with short cytoplasmic domains.

Authors:  F Mammano; E Kondo; J Sodroski; A Bukovsky; H G Göttlinger
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

9.  CD4-independent infection by HIV-2 is mediated by fusin/CXCR4.

Authors:  M J Endres; P R Clapham; M Marsh; M Ahuja; J D Turner; A McKnight; J F Thomas; B Stoebenau-Haggarty; S Choe; P J Vance; T N Wells; C A Power; S S Sutterwala; R W Doms; N R Landau; J A Hoxie
Journal:  Cell       Date:  1996-11-15       Impact factor: 41.582

10.  An internalization signal in the simian immunodeficiency virus transmembrane protein cytoplasmic domain modulates expression of envelope glycoproteins on the cell surface.

Authors:  M M Sauter; A Pelchen-Matthews; R Bron; M Marsh; C C LaBranche; P J Vance; J Romano; B S Haggarty; T K Hart; W M Lee; J A Hoxie
Journal:  J Cell Biol       Date:  1996-03       Impact factor: 10.539

View more
  78 in total

1.  Residues within the C-terminal arm of the herpes simplex virus 1 glycoprotein B ectodomain contribute to its refolding during the fusion step of virus entry.

Authors:  Sarah A Connolly; Richard Longnecker
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

2.  C-terminal tyrosine residues modulate the fusion activity of the Hendra virus fusion protein.

Authors:  Andreea Popa; Cara Teresia Pager; Rebecca Ellis Dutch
Journal:  Biochemistry       Date:  2011-01-20       Impact factor: 3.162

3.  Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization.

Authors:  Emma T Crooks; Penny L Moore; Douglas Richman; James Robinson; Jeffrey A Crooks; Michael Franti; Norbert Schülke; James M Binley
Journal:  Hum Antibodies       Date:  2005

4.  Polybasic KKR motif in the cytoplasmic tail of Nipah virus fusion protein modulates membrane fusion by inside-out signaling.

Authors:  Hector C Aguilar; Kenneth A Matreyek; Daniel Y Choi; Claire Marie Filone; Sophia Young; Benhur Lee
Journal:  J Virol       Date:  2007-02-14       Impact factor: 5.103

5.  Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.

Authors:  Hongru Li; Chati Zony; Ping Chen; Benjamin K Chen
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

6.  Restricted lateral mobility of plasma membrane CD4 impairs HIV-1 envelope glycoprotein mediated fusion.

Authors:  Satinder S Rawat; Christina Zimmerman; Benitra T Johnson; Edward Cho; Stephen J Lockett; Robert Blumenthal; Anu Puri
Journal:  Mol Membr Biol       Date:  2008-01       Impact factor: 2.857

7.  Differential functional phenotypes of two primary HIV-1 strains resulting from homologous point mutations in the LLP domains of the envelope gp41 intracytoplasmic domain.

Authors:  Jason T Newman; Timothy J Sturgeon; Phalguni Gupta; Ronald C Montelaro
Journal:  Virology       Date:  2007-06-19       Impact factor: 3.616

8.  Enhanced central nervous system transduction with lentiviral vectors pseudotyped with RVG/HIV-1gp41 chimeric envelope glycoproteins.

Authors:  Antonio Trabalza; Ioanna Eleftheriadou; Argyro Sgourou; Ting-Yi Liao; Petros Patsali; Heyne Lee; Nicholas D Mazarakis
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103

9.  Membrane structure correlates to function of LLP2 on the cytoplasmic tail of HIV-1 gp41 protein.

Authors:  Alexander L Boscia; Kiyotaka Akabori; Zachary Benamram; Jonathan A Michel; Michael S Jablin; Jonathan D Steckbeck; Ronald C Montelaro; John F Nagle; Stephanie Tristram-Nagle
Journal:  Biophys J       Date:  2013-08-06       Impact factor: 4.033

10.  Oregano Oil and Its Principal Component, Carvacrol, Inhibit HIV-1 Fusion into Target Cells.

Authors:  S Mediouni; J A Jablonski; S Tsuda; A Barsamian; C Kessing; A Richard; A Biswas; F Toledo; V M Andrade; Y Even; M Stevenson; T Tellinghuisen; H Choe; M Cameron; T D Bannister; S T Valente
Journal:  J Virol       Date:  2020-07-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.